Skip to main content
Premium Trial:

Request an Annual Quote

Sysmex Gets Japanese Manufacturing, Marketing Approval for Colorectal Cancer Screening Assay

NEW YORK – Sysmex announced today that it has obtained manufacturing and marketing approval from the Japanese Ministry of Health, Labor, and Welfare for its OncoBEAM RAS Colorectal Kit which tests for mutations in the RAS gene in blood-based circulating tumor DNA (ctDNA) for late-stage CRC patients.

Sysmex believes that physicians can use the assay to help determine whether to use anti-EGFR drugs during treatment.

The firm said the recent approval will provide Japanese CRC patients with a viable alternative to tissue testing for cancer detection, in addition to speeding up delivery of molecular information required to accurately prescribe therapies.

Sysmex plans to launch an OncoBEAM RAS CRC Assay service to further expand adoption in the Japanese population, as well as apply for national insurance coverage.

Jointly developed by Sysmex and Merck KGgA, the kit received CE marking in 2016.

The Scan

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.

Using Bees to Gain Insights into Urban Microbiomes

As bees buzz around, they pick up debris that provides insight into the metagenome of their surroundings, researchers report in Environmental Microbiome.

Age, Genetic Risk Tied to Blood Lipid Changes in New Study

A study appearing in JAMA Network Open suggests strategies to address high lipid levels should focus on individuals with high genetic risk and at specific ages.

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.